Review of the Lynch syndrome: History, molecular genetics, screening, differential diagnosis, and medicolegal ramifications

Clinical Genetics

Volumn 76, Issue 1, 2009, Pages 1-18

  Lynch, Henry T ^a   Lynch, P M ^b   Lanspa, S J ^a   Snyder, C L ^a   Lynch, J F ^a   Boland, C R ^c  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer; Endometrial cancer; Hereditary cancer; Hereditary nonpolyposis colorectal cancer; Immunohistochemistry; Lynch syndrome; Microsatellite instability; Mismatch repair; Mismatch repair genes

Indexed keywords

FLUOROURACIL; PROTEIN MLH1; PROTEIN MSH2;

ANAMNESIS; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER SCREENING; CANCER SURVIVAL; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; DIFFERENTIAL DIAGNOSIS; DNA DETERMINATION; ENDOMETRIUM CANCER; FAMILIAL CANCER; GENETIC COUNSELING; GENETIC SCREENING; HOMOZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICOLEGAL ASPECT; MISMATCH REPAIR; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; REVIEW;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETIC COUNSELING; GENETIC PRIVACY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; INFORMED CONSENT; MASS SCREENING;

EID: 67650924286     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2009.01230.x     Document Type: Review

References (145)

1. International Agency for Research on Cancer. Globocan 2002. Available at: http://www.dep.Aarc.fr/. 2008: accessed on: 25 November 2008.
2. Hampel H, Frankel WL, Martin E et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008: 26: 5783-5788.
3. Bussey HJR. Familial polyposis coli: Family studies, histopathology, differential diagnosis, and results of treatment. Baltimore, MD: Johns Hopkins University Press, 1975.
4. Bülow S, Faurschou NT, Bülow C et al. The incidence rate of familial adenomatous polyposis. Results from the Danish Polyposis Register. Int J Colorectal Dis 1996: 11: 88-91.
5. Aaltonen L, Johns L, Järvinen H et al. Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res 2007: 13: 356-361.
6. Abdel-Rahman WM, Peltomäki P. Lynch syndrome and related familial colorectal cancers. Crit Rev Oncog 2008: 14: 1-22.
7. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999: 36: 801-818.
8. Lynch HT, de la Chapelle A. Genomic medicine: Hereditary colorectal cancer. N Engl J Med 2003: 348: 919-932.
9. Lynch HT, Boland CR, Gong G et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: Diagnostic, surveillance and management implications. Eur J Hum Genet 2006: 14: 390-402.
10. Guttmacher AE, Collins FS, Carmona RH. The family history -more important than ever. N Engl J Med 2004: 351: 2333-2336.
11. United States Department of Health & Human Services. U.S. surgeon general's family history initiative. 12-29-2004. Available at: http://www.hhs.gov/familyhistory/. 2009: Accessed on: 28 January 2009.
12. Chen S, Wang W, Lee S et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006: 296: 1479-1487.
13. Lindor NM, Petersen GM, Hadley DW et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. JAMA 2006: 296: 1507-1517.
14. Balmaña J, Stockwell DH, Steyerberg EW et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 2006: 296: 1469-1478.
15. Ford JM, Whittemore AS. Predicting and preventing hereditary colorectal cancer. JAMA 2006: 296: 1521-1523.
16. Luschka H. Ueber polypose Vegetationen der gesammten Dickdarmschleimhaut. Arch Pathol Anat Physiol Klin Med 1861: 20: 133-142.
17. Lockhart-Mummery P. Cancer and heredity. Lancet 1925: I: 427-429.
18. Herrera L, Kakati S, Gibas L et al. Brief clinical report: Gardner's syndrome in a man with an interstitial deletion of 5q. Am J Med Genet 1986: 25: 473-476.
19. Bodmer WF, Bailey CJ, Bodmer J et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987: 328: 614-616.
20. Sweet K, Willis J, Zhou X-P et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005: 294: 2465-2473.
21. Bussey HJR. Historical developments in familial adenomatous polyposis. In: Herrera L, ed. Familial adenomatous polyposis. New York, NY: Alan R. Liss Inc, 1990: 1-7.
22. Warthin AS. Heredity with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. Arch Intern Med 1913: 12: 546-555.
23. Lynch HT, Shaw MW, Magnuson CW et al. Hereditary factors in cancer: study of two large Midwestern kindreds. Arch Intern Med 1966: 117: 206-212.
24. Vasen HFA, Mecklin J-P, Meera Khan P et al. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991: 34: 424-425.
25. Vasen HFA, Watson P, Mecklin J-P. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999: 116: 1453-1456.
26. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004: 96: 261-268.
27. Peltomäki P, Aaltonen L, Sistonen P. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993: 260: 810-812.
28. Lindblom A, Tannergard P, Werelius B et al. Genetic mapping of a second locus predisposing to hereditary nonpolyposis colorectal cancer. Nat Genet 1993: 5: 279-282.
29. Ionov YM, Peinado MA, Malkhosyan S et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993: 363: 558-561.
30. Aaltonen LA, Peltomaki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993: 260: 812-816.
31. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993: 260: 816-819.
32. de la Chapelle A. Microsatellite instability. N Engl J Med 2003: 349: 209-210.
33. Strand M, Prolla TA, Liskay RM et al. Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. 365: 274-276.
34. Fishel R, Lescoe MK, Rao MRS et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993: 75: 1027-1038.
35. Leach FS, Nicolaides NC, Papadopoulos N et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993: 75: 1215-1225.
36. Bronner CE, Baker SM, Morrison PT et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary nonpolyposis colon cancer. Nature 1994: 368: 258-261.
37. Papadopoulos N, Nicolaides NC, Wei Y-F et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994: 263: 1625-1629.
38. Hendriks YMC, Wagner A, Morreau H et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: Impact on counseling and surveillance. Gastroenterology 2004: 127: 17-25.
39. Nicolaides NC, Papadopoulos N, Liu B et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994: 371: 75-80.
40. Hienonen T, Laiho P, Salovaara R et al. Little evidence for involvement of MLH3 in colorectal cancer predisposition. Int J Cancer 2003: 106: 292-296.
41. Wu Y, Berends MJW, Sijmons RH et al. A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet 2001: 29: 137-138.
42. Boland CR. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer 2005: 4: 211-218.
43. Smith RA, von Eschenbach AC, Wender R et al. American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers; Also: Update 2001-testing for early lung cancer detection. CA Cancer J Clin 51: 38-75.
44. Church J, Simmang C; Collaborative Group of the Americas on Inherited Colorectal Cancer et al. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 2003: 46: 1001-1012.
45. National Comprehensive Cancer Network. Practice guidelines in oncology. Available at: http://www.nccn.org/professionals/physician_gls/ default.asp 2008: Accessed on: 2 April 2008.
46. Winawer S, Fletcher R, Rex D et al. Colorectal cancer screening and surveillance: Clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003: 124: 544-560.
47. Lynch HT, Lynch PM. Clinical selection of candidates for mutational testing for cancer susceptibility. Oncology 2006: 20: 29-34.
48. Liu B, Farrington SM, Petersen GM et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1995: 1: 348-352.
49. Lindor NM, Rabe K, Petersen GM et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: Familial colorectal cancer type X. JAMA 2005: 293: 1979-1985.
50. Jass JR, Smyrk TC, Stewart SM et al. Pathology of hereditary non-polyposis colorectal cancer. Anticancer Res 1994: 14: 1631-1634.
51. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007: 50: 113-130.
52. Boland CR, Thibodeau SN, Hamilton SR. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998: 58: 5248-5257.
53. Kane MF, Loda M, Gaida GM et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997: 57: 808-811.
54. Cunningham JM, Christensen ER, Tester DJ et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998: 58: 3455-3460.
55. Marcus V, Madlensky L, Gryfe R et al. Immunohistochemistry for hMLH1 and hMSH2: A practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol 1999: 23: 1248-1255.
56. Haugen AC, Goel A, Yamada K et al. Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res 2008: 68: 8465-8472.
57. Suraweera N, Duval A, Reperant M. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002: 123: 1804-1811.
58. Gryfe R, Kim H, Hsieh ETK et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000: 342: 69-77.
59. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003: 349: 247-257.
60. Baudhuin LM, Burgart LJ, Leontovich O et al. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer 2005: 4: 255-265.
61. Boland CR, Koi M, Chang DK et al. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: From bench to bedside. Fam Cancer 2008: 7: 41-52.
62. Chang DK, Ricciardiello L, Goel A et al. Steady-state regulation of the human DNA mismatch repair system. J Biol Chem 2000: 275: 18424-18431.
63. Peltomäki P. Lynch syndrome genes. Fam Cancer 2005: 4: 227-232.
64. Raevaara TE, Korhonen MK, Lohi H et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology 2005: 129: 537-549.
65. Blasi MF, Ventura I, Aquilina G et al. A human cell-based assay to evaluate the effects of alterations in the MLH1 mismatch repair gene. Cancer Res 2006: 66: 9036-9044z.
66. Boland CR, Fishel R. Lynch syndrome: Form, function, proteins, and basketball. Gastroenterology 2005: 129: 751-755.
67. Sanchez JA, Vogel JD, Kalady MF et al. Identifying Lynch syndrome: We are all responsible. Dis Colon Rectum 2008: 51: 1750-1756.
68. Salahshor S, Koeble K, Rubio C. Microsatellite instability and hMLH1 and hMSH2 expression analysis in familial and sporadic colorectal cancer. Lab Invest 2001: 81: 535-541.
69. Lindor NM, Burgart LJ, Leontovich O et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002: 20: 1043-1048.
70. Casey G, Lindor NM, Papadopoulos N et al. Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer. JAMA 2005: 293: 799-809.
71. Yan H, Papadopoulos N, Marra G et al. Conversion of diplody to haploidy: Individuals susceptible to multigene disorders may now be spotted more easily. Nature 2000: 403: 723-724.
72. Senter L, Clendenning M, Sotamaa K et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008: 135: 419-428.
73. Ricciardone MD, Özçelik T, Cevher B et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type I. Cancer Res 1999: 59: 290-293.
74. Gallinger S, Aronson M, Shayan K et al. Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation. Gastroenterology 2004: 126: 576-585.
75. Bandipalliam P. Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations. Fam Cancer 2005: 4: 323-333.
76. Felton KEA, Gilchrist DM, Andrew SE. Constitutive deficiency in DNA mismatch repair: Is it time for Lynch III? Clin Genet 2007: 71: 499-500.
77. Boland CR, Troncale FJ. Familial colonic cancer without antecedent polyposis. Ann Intern Med 1984: 100: 700-701.
78. Wimmer K, Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of the iceberg? Hum Genet 2008: 124: 105-122.
79. Liu B, Parsons RE, Hamilton SR et al. hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res 1994: 54: 4590-4594.
80. Froggatt NJ, Koch J, Davies R et al. Genetic linkage analysis in hereditary non-polyposis colon cancer syndrome. J Med Genet 1995: 32: 352-357.
81. Desai DC, Lockman JC, Chadwick RB et al. Recurrent germline mutation in MSH2 arises frequently de novo. J Med Genet 2000: 37: 646-652.
82. Hampel H, Frankel WL, Martin E et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005: 352: 1851-1860.
83. Green J, O'Driscoll M, Barnes A et al. Impact of gender and parent of origin on the phenotypic expression of hereditary nonpolyposis colorectal cancer in a large Newfoundland kindred with a common MSH2 mutation. Dis Colon Rectum 2002: 45: 1223-1232.
84. Nystrom-Lahti M, Kristo P, Nicolaides NC et al. Founding mutations and Alu-mediated recombination in hereditary colon cancer. Nat Med 1995: 1203-1206.
85. Moisio A-L, Sistonen P, Weissenbach J et al. Age and origin of two common MLH1 mutations predisposing to hereditary colon cancer. Am J Hum Genet 1996: 1243-1251.
86. Foulkes WD, Thiffault I, Gruber SB et al. The founder mutation MSH2*1906G-> C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet 2002: 71: 1395-1412.
87. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004: 4: 769-780.
88. Wagner A, Barrows A, Wijnen JT et al. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: High mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet 2003: 72: 1088-1100.
89. Nakagawa H, Hampel H, de la Chapelle A. Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques. Hum Mutat 2003: 22: 258.
90. Wagner A, van der Klift H, Franken P et al. A 10 Mb paracentric inversion of chromosome arm 2p inactivates MSH2 and is responsible for HNPCC in a North-American kindred. Gene Chromosome Cancer 2002: 35: 49-57.
91. Lynch HT, Coronel SM, Okimoto R. A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA 2004: 291: 718-724.
92. Clendenning M, Baze ME, Sun S et al. Origins and prevalence of the American founder mutation of MSH2. Cancer Res 2008: 68: 2145-2153.
93. Wijnen JT, Brohet RM, van Eijk R et al. Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. Gastroenterology 2009: 136: 131-137.
94. Watson P, Lin K, Rodriguez-Bigas MA et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal cancer family members. Cancer 1998: 83: 259-266.
95. Crijnen ThEM, Janssen-Heijnen MLG, Gelderblom H et al. Survival of patients with ovarian cancer due to a mismatch repair defect. Fam Cancer 2005: 4: 301-305.
96. Karran P, Bignami M. DNA damage tolerance, mismatch repair and genome instability. Bioessays 1994: 16: 833-839.
97. Koi M, Umar A, Chauhan DP et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994: 54: 4308-4312.
98. 2 cell cycle checkpoint. Cancer Res 1995: 55: 3721-3725.
99. Carethers JM, Hawn MT, Chauhan DP et al. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine. J Clin Invest 1996: 98: 199-206.
100. Aebi S, Kurdi-Haider B, Gordon R et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996: 56: 3087-3090.
101. Carethers JM, Dharam PC, Fink D et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999: 117: 123-131.
102. Elsaleh H, Joseph D, Grieu F et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000: 355: 1745-1750.
103. Carethers JM, Smith EJ, Behling CA et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004: 126: 394-401.
104. Benatti P, Gafa R, Barana D et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005: 11: 8332-8340.
105. de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2004: 109: 468-471.
106. Jover R, Zapater P, Castells A et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil themotherapy in cholorectal cancer. Gut 2006: 55: 848-855.
107. Jacob S, Aguado M, Fallik D et al. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001: 61: 6555-6562.
108. Fallik D, Borrini F, Boige V et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003: 63: 5738-5744.
109. Jass JR, Do K-A, Simms LA et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998: 42: 673-679.
110. Hamilton SR, Aaltonen LA, eds. Tumours of the digestive system. Lyon: IARC Press, 2000.
111. Smyrk TC, Watson P, Kaul K et al. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal cancer. Cancer 2001: 91: 2417-2422.
112. Brose MS, Smyrk TC, Weber B et al. Genetic predisposition to cancer. In: Kufe DW, Pollock RE, Weischselbaum RR, Bast RC Jr, Gansler TS, Holland JF et al., eds. Cancer medicine, 6th edn. Hamilton, Ontario, Canada: B.C. Decker, 2003: 241-265.
113. Järvinen HJ, Aarnio M, Mustonen H et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000: 118: 829-834.
114. Vasen HFA, Nagengast FM, Khan PM. Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 1995: 345: 1183-1184.
115. Mecklin J-P, Aarnio M, Läärä E et al. Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. Gastroenterology 2007: 133: 1093-1098.
116. Hurlstone DP, Karajeh M, Cross SS et al. The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: A prospective "back-to-back" endoscopic study. Am J Gastroenterol 2005: 100: 2167-2173.
117. de Jong AE, Hendriks YMC, Kleibeuker JH et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 2006: 130: 665-671.
118. Rijcken FEM, Hollema H, Kleibeuker JH. Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut 2002: 50: 382-386.
119. Rijcken FEM, Koornstra JJ, van der Sluis T, Boersma-van Ek W, Kleibeuker JH, Hollema H. Early carcinogenic events in HNPCC adenomas: Differences with sporadic adenomas. Dig Dis Sci 2008: 53: 1660-1668.
120. Lecomte T, Cellier C, Meatchi T et al. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin Gastroenterol Hepatol 2005: 3: 897-902.
121. East JE, Suzuki N, Stavrinidis M et al. Narrow band imaging for colonoscopic surveillance in hereditary non-polyposis colorectal cancer. Gut 2008: 57: 65-70.
122. Stoffel EM, Turgeon DK, Stockwell DH et al. Missed adenomas during colonoscopic surveillance in individuals with Lynch syndrome (hereditary nonpolyposis colorectal cancer). Cancer Prev Res 2008: 1: 470-475.
123. Dunlop MG, Farrington SM, Carothers AD et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997: 6: 105-110.
124. Vasen HFA, Wijnen JT, Menko FH et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996: 110: 1020-1027.
125. Schmeler KM, Lynch HT, Chen L-M et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006: 354: 261-269.
126. Lynch HT. Family Information Service and hereditary cancer. Cancer 2001: 91: 625-628.
127. Aktan-Collan K, Mecklin J-K, Jarivnen HJ et al. Predictive genetic testing for hereditary non-polyposis colorectal cancer: Uptake and long-term satisfaction. Int J Cancer (Pred Oncol) 2000: 89: 44-50.
128. Wasielewski M, Vasen H, Wijnen J et al. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer. Clin Cancer Res 2008: 14: 4989-4994.
129. Cybulski C, Górski B, Huzarski T et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004: 75: 1131-1135.
130. Cybulski C, Wokolorczyk D, Kladny J et al. Germline CHEK2 mutations and colorectal cancer risk: Different effects of a missense and truncating mutations? Eur J Hum Genet 2007: 15: 237-241.
131. Kilpivaara O, Alhopuro P, Vahteristo P et al. CHEK2 I157K associates with familial and sporadic colorectal cancer. J Med Genet 2006: 43: e34.
132. van Puijenbroek M, van Asperen CJ, Van Mil A et al. Homozygosity for a CHEK2 *1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype. J Pathol 2005: 206: 198-204.
133. Aaltonen LA, Salovaara R, Kristo P et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998: 338: 1481-1487.
134. Bessa X, Balleste B, Andreu M et al. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 2008: 6: 206-214.
135. Nagasaka T, Koi M, Kloor M et al. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology 2008: 134: 1950-1960.
136. Llor X, Pons E, Xicola RM et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res 2005: 11: 7304-7310.
137. Valle L, Perea J, Carbonell P et al. Clinicopathologic and pedigree differences in Amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status. J Clin Oncol 2007: 25: 781-786.
138. Sánchez-de-Abajo A, de la Hoya M, von Puijenbroek M et al. Molecular analysis of colorectal cancer tumors from patients with mismatch repair-proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. Clin Cancer Res 2007: 13: 5729-5735.
139. Hudson KL, Holohan MK, Collins FS. Keeping pace with the times -the Genetic Information Nondiscrimination Act of 2008. N Engl J Med 2008: 358: 2661-2663.
140. Offit K, Thom P. Ethical and legal aspects of cancer genetic testing. Semin Oncol 2007: 34: 435-443.
141. Offit K, Groeger E, Turner S et al. The "duty to warn" a patient's family members about hereditary disease risks. JAMA 2004: 292: 1469-1473.
142. Online Mendelian Inheritance in Man. McKusick-Nathans Institute for Medical Genetics, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD). Available at: http://www.ncbi.nlm.nih.gov/omim. 2008: accessed on: 25 November 2008.
143. Watson P, Vasen HFA, Mecklin J-P et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008: 123: 444-449.
144. Barrow E, Robinson L, Alduaij W et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: A report of 121 families with proven mutations. Clin Genet 2009: 75: 141-149.
145. Laghi L, Bianchi P, Roncalli M et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004: 96: 1402-1403.